56
Participants
Start Date
March 27, 2014
Primary Completion Date
June 1, 2023
Study Completion Date
January 16, 2024
Abatacept
The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
Dana-Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Dana-Farber Cancer Institute
OTHER
Beth Israel Deaconess Medical Center
OTHER